ArticleWorld journal of nuclear medicine2026
Early Side Effects of rhTSH-Aided Radioiodine Ablation and Treatment of Differentiated Thyroid Cancer: A Real-World Experience.
Article in World journal of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We aimed to investigate the early side effects of recombinant human thyroid-stimulating hormone (rhTSH)-aided radioactive iodine (RAI) administration in an unselected cohort of patients with differentiated thyroid cancer (DTC) in the real-world setting. Methods: During follow-up (at 6 weeks, 6 months, and 12 months post-RAI) of patients with DTC who received rhTSH-aided RAI, we used a standardized questionnaire to collect patient-reported side effects of RAI. We investigated the factors that impact the occurrence of RAI-associated side effects. Results: A total of 111 patients with a female predominance (66.7%) and a mean age of 51.1 ± 16.0 years were included, including 13 patients (11.7%) who had previously received RAI. The predominant tumor histology was papillary thyroid cancer, with 91.0% of patients having stage I/II disease. At 6-week follow-up, loss of taste/smell, nausea, salivary gland pain or swelling, dry mouth, and neck pain were reported by 45.9, 37.8, 30.6, 36.9, and 20.7% of patients, respectively. In most patients, these side effects lasted for less than 1 week. At 6-month post-RAI, 13 patients reported lingering RAI-associated side effects, including 4 and 3 patients who reported dry mouth and dry eyes, respectively. A 12-month post-RAI, one patient each reported dry eyes, watery eyes, and fatigue as RAI side effects. Women were at higher risk of neck pain, while young patients were more likely to experience nausea ( Conclusion: rhTSH-aided RAI administration in DTC patients is associated with tolerable side effects, most of which resolved within weeks of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.